Brief: Palisade Bio Gives Update On U.S. Phase 2 Study Evaluating LB1148

Palisade Bio

16/12/2022 13:55

Dec 16 (Reuters) - Palisade Bio Inc  PALI.O :
    * PALISADE BIO PROVIDES UPDATE ON U.S. PHASE 2 STUDY
EVALUATING
LB1148 FOR POST-SURGICAL ABDOMINAL ADHESIONS
    * PALISADE BIO INC - TOPLINE DATA READOUT FROM STUDY
EXPECTED IN
FIRST HALF OF 2023
    * PALISADE BIO INC - COMPANY ENROLLED A TOTAL OF 35 OF
PLANNED 70
PATIENTS IN ITS PHASE 2 STUDY
    * PALISADE BIO INC - OF PATIENTS ENROLLED, 31 HAVE COMPLETED
THEIR
FIRST SURGERY, AND NINE HAVE COMPLETED A SECOND SURGERY
    * PALISADE BIO - DATA COLLECTED TO DATE IS SUFFICIENT FOR
ITS
EVALUATION PURPOSES, AND FOR SUCH REASON, CO IS VOLUNTARILY
CEASING ENROLLMENT IN TRIAL
    * PALISADE BIO INC - CURRENTLY DESIGNING A DOSE OPTIMIZATION
STUDY, WITH ENROLLMENT EXPECTED TO COMMENCE IN FIRST HALF OF
2023

Source text for Eikon:  ID:nGNX6rZvV8 
Further company coverage:  PALI.O 
 ((Reuters.Briefs@thomsonreuters.com;))